What is Good Clinical Practice in Research?

Introduction to Good Clinical Practice:

Good Clinical Practice (GCP) is the international ethical, scientific, and practical standard by which all clinical research is conducted. Everyone involved in research must be properly trained or experienced to perform the tasks that have been assigned to them as per GCP (Good Clinical Practice) guidelines.

The current system of Good Clinical Practice (GCP) clinical research has changed, partly due to disclosures about past incidents in which research participants were mistreated. Regulations and ethical guidelines pertaining to the protection of human research subjects gained significant traction as a result of the publicity surrounding these incidents.

Various research kinds might call for varying degrees of training, and some researchers are already qualified and experienced in their field. While GCP training may also be beneficial for researchers conducting other kinds of clinical trials, there are other training programs that are more pertinent to their field of study.

Why is GCP Clinical Research Training Essential?

Any of the individuals involved in clinical research must be trained in the basics of Good Clinical Practice as it is crucial to ensure their awareness of the the standards that have been set.

• All research involving human subjects must adhere to GCP (Good Clinical Practice) guidelines, which are widely accepted and anticipated.
• GCP is a general concept that can be applied to any research protocol; it is not protocol-specific.

On average, the self-paced course is required to take anywhere from four to six hours. Every three years, NIH-affiliated staff members must complete the course in order to ensure that all researchers are informed about developments pertaining to GCP (Good Clinical Practice) guidelines, such as modifications to federal regulations concerning the protection of vulnerable research participants, electronic data, or privacy protections. It is recommended that others review and follow the guidelines provided by their institutional, governing, and other committees for recertification.

ICH GCP Clinical Research Principles

Ethics

• Conducting clinical trials ethically.
• The benefits outweigh the risks.
• Subjects’ rights, safety, and well-being take precedence.

Science and Protocol

• The trial is supported by nonclinical and clinical data.
• Adherence to a scientifically sound and detailed protocol.

Responsibilities

• Prior IRB/IEC approval before proceeding.
• Medical care/decisions made by a qualified physician.
• Each individual is qualified (by education, training, and experience) to carry out his or her responsibilities.

Consent with Knowledge

• Prior to participation, every subject freely gives their consent.

Data Integrity and Quality

• Reliable reporting, interpretation, and validation.
• Maintains record confidentiality in Investigational Products.
• GMP compliance and protocol adherence.

Quality Assurance/Quality Control

• Systems and procedures for ensuring the quality of all aspects of the Clinical Trial.

Basics of Good Clinical Practice in Research

In addition to providing a standard for guaranteeing clinical trial compliance, implementation, data collection, monitoring, and reporting (e.g., data on safety, study status, protocol deviations, unexpected problems, or final results), GCP (Good Clinical Practice) guidelines also outline the responsibilities of investigators, sponsors, monitors, and institutional review boards (IRBs).

GCP (Good Clinical Practice) guidelines cover the design, conduct, and reporting of clinical trials (including safety data, study status, protocol deviations, unanticipated issues, or final data).

What are the GCP (Good Clinical Practice) Guidelines?

A scientific quality standard for planning, carrying out, documenting, and reporting clinical trials involving human subjects is called good clinical practice, or GCP. The GCP guidelines were proposed in collaboration with the International Council for Harmonization (ICH). The ICH GCP (Good Clinical Practice) Guidelines serve two functions:

• To protect the rights, safety, and confidentiality of Clinical Trial participants.
• To ensure that the data collected in Clinical Trials, as well as the results reported, are accurate and credible.

What is Good Clinical Practice in Research?

The European Union (EU), Japan, and the United States needed a common standard for clinical data acceptance by regulatory bodies, and that was the aim of the GCP (Good Clinical Practice) Guidelines. The guidelines were developed with consideration for the most recent best clinical practices from the World Health Organization (WHO), Australia, Canada, the European Union, Japan, and the United States.

When producing clinical trial data for submission to regulatory bodies, these guidelines ought to be adhered to. The guidelines outlined in the Good Clinical Practice (GCP) guidelines can also be applied to other clinical studies that have the potential to affect the safety and welfare of human subjects.

Different Responsibilities Involved in GCP Clinical Research?

All parties involved in a clinical trial share responsibility for GCP Clinical Research, including:

• Sponsors
• Contract Research Organizations (CROs)
• Investigators
• Study site staff
• IRBs
• Research Subjects
• FDA/other regulators

Responsibilities of the Sponsor:

• Obtain regulatory approval, as needed, before beginning a study
• Begin, withhold, or discontinue studies as needed
• Protocol development is often done in collaboration with one or more clinical investigators
• Refrain from commercializing investigational products
• Control the distribution and return of research products
• Disseminate appropriate information to Investigators – Investigator’s Brochure for pharmaceutical studies & Update as needed
• Obtain financial disclosure information from investigators
• Select qualified individuals to monitor the conduct of the studies
• Ensure adequate clinical study monitoring
• Requires access to site and subject records (privacy laws apply) – Provides quality control for subject protection and data integrity & Enables clinical investigator compliance assurance
• Evaluate and report adverse experiences
• Keep adequate records
• Submit all required reports, including safety reports, annual/progress reports, and final reports

Responsibilities of the Investigator:

• Personal conduct and/or supervision of the study
• Cannot contract out any responsibilities; is entirely responsible for study conduct at the site
• Must ensure that anyone delegated study duties has the necessary qualifications and training, and must meet with study staff regularly
• Communicate with the IRB – Initial approval before study initiation, Amendments/progress reports/continuing review, & “Safety” reports
• Protocol adherence – No deviation without a prior sponsor and IRB approval
• Control of investigational products – Detailed records, receipts, use, and disposition as per protocol should be designed to facilitate compliance
• Maintaining randomization and blinding; unblinding only for medical emergencies and fully documented
• Safety reporting – Recognizing and reporting all adverse events & Paying special attention to serious and unexpected events
• Reporting to sponsor, IRB, and regulatory bodies as required
• Recordkeeping – Case histories that are accurate and complete for each study subject, Keep a record of those who received investigational products and controls, which include: Original documents (hospital charts, clinical laboratory reports, x-rays, ECGs, subject diaries, pharmacy records)
• Data quality and integrity must be maintained per applicable regulations

Responsibilities of the IRBs:

• Membership – Must be diverse and independent, Must include at least 5 members, Must include at least one member from the scientific area, Must include at least one member who is from a nonscientific area, Must include at least one member who is not otherwise connected to the institution, & Non-voting consultants/experts invited as needed
• Written procedures – Initial and ongoing evaluation, Frequency of change review and verification, Prompt reporting of changes, No changes without IRB review and approval unless to eliminate an obvious immediate hazards, Prompt reporting of unexpected problems, Prompt notification of serious or ongoing non-compliance, & Prompt notification of suspension or termination of IRB approval
• Research review – Full board, expedited review, Criteria for approval are met, & Perform ethical reviews
• Ensure proper expertise for scientific review
• Examine the target subject population to ensure proper inclusion/exclusion criteria and recruitment
• Examine the investigator’s credentials and ability to supervise and conduct the study at the site
• Consider subject privacy and data confidentiality
• Making decisions – Normally at a convened meeting with a quorum present, unless qualifies for expedited review, Decisions should be made using written procedures (approval, modifications requested to secure approval, disapproval), No IRB member who has a conflict of interest should take part, & Non-members are barred from participating in discussions and voting
• Ongoing review – As needed based on the risk of the study, but at least once a year, Unless it qualifies for expedited review, substantive, and at a convened meeting
• Communicating decisions – In correspondence with the investigator and the institution, Revision suggestions when changes are needed, & Reasons for disapproval or prior approval termination/suspension
• Keeping adequate records (e.g., correspondence, copies of all research proposals, approved sample ICDs, meeting minutes) and retaining records as required by applicable regulations.

Importance of Informed Consent in GCP Clinical Research?

Informed consent is most importantly for a continuous process. After being fully informed about a research study verbally from study personnel and receiving documentation in the form of an informed consent form that is written, signed, and dated, an individual voluntarily consents to participate in the study. Consent from participants will be continuously sought throughout the study, and they will be informed of any changes to the research as well as any other relevant information that might affect their choice to continue participating.

Institutional Review Boards (IRBs) & Human Subjects Protection:

According to FDA regulations, scientific studies intended to produce proof of the safety and effectiveness of biological products, medical devices, and investigational drugs (both human and animal) are reviewed by the Institutional Review Board.

When conducting these Good Clinical Practice GCP studies, doctors and other qualified experts—referred to as “Clinical Investigators”—must abide by all relevant laws and regulations. The purpose of these laws and regulations is to guarantee the integrity of clinical data used to support product approvals while simultaneously safeguarding the rights, welfare, and safety of human subjects.

Research can be approved, modified (to obtain approval), or denied by an IRB. In order to protect the rights and welfare of human research subjects, this group review is crucial.

Importance of Patient Safety in GCP Clinical Research:

Participant safety is a broad topic that covers all aspects and fundamentals of Good Clinical Practice (GCP). Developing protocols, overseeing quality control, following regulations, and taking ethical issues into account are a few of the things that go into ensuring participant safety.

Points Regarding Participant Safety Protection:

• The obligation to safeguard study participants’ welfare does not end when an investigation receives approval from the Data and Safety Monitoring Board (DSMB) or the Institutional Review Board (IRB), or when a participant signs an informed consent form. A variety of parties must constantly safeguard study participants’ interests during a clinical research study.
• Ultimately, trial participants cannot be fully protected by a single person or entity. Every trial needs to follow a methodical plan to ensure that all parties understand and carry out their responsibilities.
• Research team members who possess adequate knowledge of clinical trials, statistics, the clinical disorder being studied, and the investigational product must routinely review the study data to guarantee that events are appropriately interpreted and reported.
• A key component of participant safety is open communication amongst all research staff.

Any medical decisions pertaining to Clinical Trials are made by the principal investigator or a physician-licensed sub-investigator. When a concurrent illness that the investigator learns about necessitates treatment, the subject must be informed, and the investigator must ensure that the subject receives appropriate medical attention for any unfavorable events.

The Food and Drug Administration (FDA) of the United States requires the investigator to report all unexpected problems involving risk to human subjects to FDA as soon as possible. As well as reporting to both the sponsor and the IRB.

Regardless of whether the adverse event is thought to be drug-related or not, a reasonable probability analysis of the event’s potential drug cause must be included in any serious adverse event report.

Role of Quality Assurance in GCP Clinical Research?

The process of conducting systematic, planned actions to ensure that a trial is carried out in accordance with the protocol, the tenets of Good Clinical Practice (GCP), and other pertinent regulatory requirements is known as quality assurance (QA) in GCP Clinical Research Studies.

To guarantee that study results are correctly interpreted, high-quality data is necessary. Inaccurate conclusions can arise from data that is of poor quality or incomplete. Timely completion of studies is ensured by closely monitoring quality standards. Timely completion of high-quality studies closes the knowledge gap between research and practice by accelerating the delivery of new, effective treatments to patients.

Establishing and maintaining QA systems is ultimately the responsibility of the Sponsor, even though it is common for CROs to be assigned tasks and responsibilities related to QA and monitoring. This responsibility includes overseeing all QA initiatives and any trial-related tasks completed or managed on behalf of the Sponsor by outside parties (like the CRO or a subcontractor to the CRO).

The following GCP Clinical Research activities are carried out by QA monitors:

• Perform the initial, interim, and final visits.
• If necessary, carry out centralized monitoring.
• When necessary or appropriate, offer training on GCP (Good Clinical Practice) guidelines and protocol-specific issues.
• Take action on problems found during earlier monitoring visits.
• Submit reports as needed to the sponsor and other relevant parties.

Investigators and all protocol team members are expected to perform their duties with meticulous attention to detail in order to guarantee that the trial is executed to the highest standards of quality.

The research protocol needs to succinctly and clearly outline each of the following aspects of the study:

• Why is the study being done?
• How will the study be conducted?
• Where will it be conducted? (For multi-site trials, site-specific information may be incorporated into local protocol versions)
• Who is involved in the study?
• When will the study interventions occur?